Table 1 Baseline clinical characteristics of the 3 groups
| Â | DM (n=452) | PH (n=236) | NGT (n=140) | P value |
|---|---|---|---|---|
Age, years | 70 (62–74)* | 67 (59–72) | 69 (62–74) | 0.002 |
Male | 347 (76.7) | 203 (86.0)†‡ | 103 (73.5) | 0.004 |
Hypertension | 380 (84.0) | 185 (78.3) | 104 (74.2) | 0.019 |
Dyslipidemia | 295 (65.2) | 164 (69.4) | 101 (72.1) | 0.24 |
Current smoking | 119 (26.3) | 74 (31.3) | 34 (24.2) | 0.24 |
Previous PCI | 249 (55.0)*†| 104 (44.0) | 66 (47.1) | 0.015 |
Previsou CABG | 33 (7.2) | 9 (3.8) | 10 (7.1) | 0.18 |
Previous MI | 148 (32.7) | 63 (26.6) | 39 (27.8) | 0.2 |
Previous CI | 55 (12.1) | 27 (11.4) | 11 (7.8) | 0.36 |
Multivessel disease | 128 (28.3) | 59 (25.1) | 29 (20.7) | 0.18 |
BMI, kg/m2 | 24.3 (22.1-26.4)†| 24.7 (22.9-26.6)†| 23.2 (21.0-25.7) | <0.001 |
LVEF, % | 61.0 (50.0-68.0)* | 64.0 (55.0-69.0) | 64.0 (50.2-68.0) | 0.017 |
eGFR, ml/min./1.73m2 | 64.9 (51.4-76.1) | 66.2 (57.5-75.1) | 65.6 (54.6-79.6) | 0.17 |
Stent type | Â | Â | Â | 0.057 |
BMS | 255 (56.4) | 146 (61.8) | 94 (67.1) | Â |
DES | 197 (43.6) | 90 (38.2) | 46 (32.9) | Â |
Medication at discharge | Â | Â | Â | Â |
Aspirin | 452 (100.0) | 236 (100.0) | 140 (100.0) | - |
Thienopyridine | 452 (100.0) | 236 (100.0) | 140 (100.0) | - |
β-blocker | 136 (30.0) | 78 (33.0) | 41 (29.2) | 0.66 |
ACE-I | 117 (25.8) | 48 (20.3) | 27 (19.2) | 0.12 |
ARB | 178 (39.3) | 86 (36.0) | 46 (32.8) | 0.33 |
Statin | 285 (63.0) | 139 (58.9) | 79 (56.4) | 0.29 |
OHA | 325 (71.9) | 0 (0.0) | 0 (0.0) | <0.001 |
Insulin | 64 (14.1) | 0 (0.0) | 0 (0.0) | <0.001 |